Doctor Clay Siegall has been working to advance the biotechnology field and cancer research since 1988. His background in the fields include working for the National Cancer Institute, National Institutes of Health from 1988 to 1991 as well as working for the Bristol-Myers Squibb Pharmaceutical Research Institute 1991 to 1997. Since then he has remained Chief Executive Officer (CEO) of this prominent and progressive company.
A very large part of Dr. Siegall forming Seattle Genetics was his passion for the growing field of monoclonal antibodies in 1997, he chose to pursue the field and start his own company. He did this instead of going back to the east coast when Bristol-Meyers Squibb when they closed their lab in Seattle in 1997.
During his time leading Seattle Genetics, Dr. Siegall has helped with capital-raising activities with both public and private financings, totaling more than $675 million which did include the company’s initial public offerings in 2001. One of the main driving forces for the capital is Seattle Genetics’ first commercial product, ADCETRIS® (brentuximab vedotin). Revolutionary and innovative, ADCETRIS® (brentuximab vedotin) is an Antibody-Drug Conjugate (ADC) that targets the antigens specific to cancers, Hodgkin lymphoma in particular.
Encouraged by strong clinical trials and highly positive results, ADCETRIS® (brentuximab vedotin) has been approved in 47 countries for use against cancer. This ADC and several others developed by Seattle Genetics are improving the overall health of patients by targeting the cancer specific antigens for cancer growth and reproduction, instead of targeting the whole area the cancer is in, healthy cells included. As a result, people are having fewer relapses and better recovery times with these new technologies.
With his passion and personable nature, Dr. Siegall works for his heart and the people he knows he, and his company, can help. Their creativity and drive consistently push the envelope of the ADC pharmaceutical industry in all the right ways.